RecruitingNot applicableNCT06920134
Rare condition
Pure autonomic failure
11
studies recruiting now
as of 7 Sept 2026
70
studies registered in total
as of 7 Sept 2026
6
countries with a recruiting site
as of 7 Sept 2026
9 Apr 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNot applicableNCT04782830
Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms
RecruitingNCT01799915
Natural History Study of Synucleinopathies
RecruitingNot applicableNCT05908760
CO2 Rebreathing in nOH: A Proof-of-Concept Pilot Study
RecruitingNot applicableNCT05489575
CPAP for the Treatment of Supine Hypertension
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 11 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Pure autonomic failure study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Pure autonomic failure
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
2 approved treatments and 18 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Droxidopa (Northera)Approved: Ioflupane I 123 (Celsunax)
Phase 3Riluzole (Exservan)
Phase 3Rifampin (Eremfat)
Phase 3Verdiperstat
Phase 3Amlenetug
Phase 3Epigalocatechin Gallate
Phase 2Inosine
Phase 2Lithium Carbonate (Camcolit 250)
Phase 2Foralumab
+ 10 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).